Company intelligence / Profile preview

Crux Biomedical

Menlo Park, California, United Statescruxbiomedical.com ↗

Ownership: Private
Development stage: Commercial

Overview

Crux Biomedical developed the Crux Vena Cava Filter (VCF), a minimally invasive implantable device designed for easy deployment and retrieval to prevent pulmonary embolism. The filter received FDA clearance and CE mark approval following pivotal clinical trials demonstrating safety and efficacy. The company was acquired by Volcano Corporation in December 2012 for $36 million[1][2][4].

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Crux Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crux Biomedical.

Explore the full profile